Molecular nuclear therapies for thyroid carcinoma

Area of Science:

• Endocrinology
• Oncology
• Nuclear Medicine

Background:

• Thyroid cancer is the most common endocrine malignancy, with subtypes including differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), and anaplastic thyroid carcinoma (ATC).
• Established molecular nuclear therapies have been used for decades to treat various thyroid cancer types.

Purpose of the Study:

• To review established and emerging molecular nuclear therapies for thyroid carcinoma.
• To discuss the efficacy and limitations of current treatments and explore novel therapeutic concepts.

Main Methods:

• Review of established therapeutic modalities, including Iodine-131 (I-131) for DTC.
• Discussion of alternative therapies such as radioactively labeled somatostatin analogues for MTC and some DTC cases.
• Exploration of preclinical findings on NIS re-induction or transfection for ATC and dedifferentiated DTC, and development of new NIS substrates.

Main Results:

• I-131 is effective for DTC but not for other thyroid cancer subtypes or dedifferentiated DTC.
• Somatostatin analogues show promise for MTC and some DTC cases.
• NIS re-induction/transfection presents a potential therapeutic strategy for ATC and dedifferentiated DTC.

Conclusions:

• While I-131 remains a cornerstone for DTC, its limitations necessitate alternative approaches for other thyroid cancer types.
• Emerging strategies like somatostatin analogues and NIS-based therapies offer new hope for treating refractory and advanced thyroid cancers.
• Continued research into novel molecular nuclear therapies is crucial for improving outcomes in all forms of thyroid carcinoma.